Pliant Therapeutics Inc
PLRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$78.02M
Close$
$0.27
77.4% downside
Current Fair Value
77.4% downsideOvervalued by 77.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $78.02 Million |
|---|---|
| Enterprise Value | $84.61 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.43 |
| Beta | 1.21 |
| Outstanding Shares | 61,803,467 |
Return
| Return on Equity | -68.55% |
|---|---|
| Return on Assets | -55.88% |
| Return on Invested Capital | -60.59% |
Valuation & Multiples
| P/E Ratio | -0.69 |
|---|---|
| PEG | 1.07 |
| Price to Sales | - |
| Price to Book Ratio | 0.59 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.73 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.34 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.0840▲ 91.85% |
|---|---|
| Total Calls | 59,500▼ 62.13% |
| Total Puts | 124,000▼ 32.28% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 80.96%▲ 4.92% |
|---|---|
| Total Invested | $62.48M▲ 8.59% |
| Investors Holding | 94▼ 5.00% |
ESG Score
No data
About Pliant Therapeutics Inc
CEO: Bernard Coulie